De-risk the development of novel therapies. Fueled by AI.

Based on a unique wealth of proprietary and expertly curated data, Intelligencia has been pioneering the use of Machine Learning algorithms to assess, quantify, and reduce the risk of clinical development.

Software that delivers sustained, positive impact.

Our solutions enable you to minimize risks in drug development, streamline productivity and lower cost across key aspects of pre-clinical and clinical development, Portfolio Strategy, and Business Development.

Newsroom

Learn more about Intelligencia through our latest press clippings and more!

CB Insights

Intelligencia Demo at CB Insights Future of Health 2021

December 08, 2021

CB Insights

CNS Summit

Vangelis Vergetis presenting at the 2021 CNS Summit

November 08, 2021

CNS Summit

Businesswire

Intelligencia Raises $12M to Reduce the Risk of Clinical Research, Improve R&D Productivity, and Accel erate Scientific Breakthroughs

August 10, 2021

Businesswire

FORBES AI

America’s most promising AI companies of 2021

April 28, 2021

FORBES AI

AACR

Assessing drug development risk using Big Data and Machine Learning

December 22, 2020

AACR

Bioarxiv

A Machine Learning approach for assessing drug development risk

October 09, 2020

Bioarxiv

bcg.com

Harnessing the Power of AI in Greece: Embarking on the Path to Value

October 09, 2020

bcg.com

PharmaTech Outlook

Intelligencia.ai: Machine learning: A Catalyst for Drug Development

October 09, 2020

PharmaTech Outlook

pharmatoptalent.com

Take the risk out of clinical drug development

September 29, 2020

pharmatoptalent.com

Optimizing Real World Data for Therapeutic Development: The Role of Artificial Intelligence

September 25, 2020

Fortune Greece

Dimitrios Skaltsas: AI at the heart of drug-development company

June 13, 2020

Fortune Greece

What our users are saying

We innovate and evolve in a fast-moving environment - Intelligencia's technology has helped us uncover valuable insights and stay ahead of the curve
— Researcher at I/O Biotech in the Bay Area

Thank you for informing and enabling our portfolio strategy with a continuous stream of insights across emerging trends and salient competitive threats in our space
— VP of Portfolio Strategy, Biotech

Intelligencia has provided great search and data automation capabilities on very specific scientific topics, the results are truly enhancing our strategy.
— Associate Director of External Innovation, Pharmaceutical company

Intelligencia's platform to assess the Probability of Success of our portfolio programs is very powerful; it helps us make critical decisions in portfolio management.
— Head of Global Portfolio Management, Pharmaceutical company

Was speaking to one of my colleagues earlier today who used Intelligencia for one of the targets that we have been looking at and he loved it. We went through the results together and it made me realize that it would be great to have access and to start using this software
— Director of External Innovation, Pharmaceutical company in the Boston Area

Intelligencia brings data to the table along with some really insightful analyses
— Protocol Review Manager at Research Center